Patents by Inventor H. Donald Burns

H. Donald Burns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiolabeled glycine transporter inhibitors
    Patent number: 7834031
    Abstract: The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: November 16, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: H. Donald Burns, Terence G. Hamill, Craig W. Lindsley
  • Radiolabeled cannabinoid-1 receptor modulators
    Patent number: 7754188
    Abstract: The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: July 13, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: H. Donald Burns, Alex M. Chen, Raymond E. Gibson, Mark T. Goulet, William K. Hagmann, Terence G. Hamill, James P. Jewell, Linus S. Lin, Ping Liu, Andrey V. Peresypkin
  • Radiolabeled Glycine Trasporter Inhibitors
    Publication number: 20090269278
    Abstract: The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.
    Type: Application
    Filed: September 29, 2005
    Publication date: October 29, 2009
    Inventors: H. Donald Burns, Terence G. Hamill, Craig W. Lindsley
  • Radiolabeled neurokinin-1 receptor antagonists
    Patent number: 7354935
    Abstract: The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: April 8, 2008
    Assignee: Merck & Co. Inc.
    Inventors: H. Donald Burns, Wai-si Eng, Raymond E. Gibson, Terence G. Hamill
  • Substituted amides
    Publication number: 20060115425
    Abstract: The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.
    Type: Application
    Filed: June 25, 2004
    Publication date: June 1, 2006
    Inventors: H. Donald Burns, Alex Chen, Raymond Gibson, Mark Goulet, William Hagmann, Terence Hamill, James Jewell, Linus Lin, Ping Liu, Andrey Peresypkin
  • Radiolabeled neurokinin-1 receptor antagonists
    Publication number: 20050214204
    Abstract: The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.
    Type: Application
    Filed: September 19, 2003
    Publication date: September 29, 2005
    Inventors: H. Donald Burns, Wai-si Eng, Raymond Gibson, Terence Hamill
  • Radiolabeled neuropeptide Y Y5 receptor antagonists
    Patent number: 6939966
    Abstract: The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: September 6, 2005
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: H. Donald Burns, Raymond E. Gibson, Terence G. Hamill, Takehiro Fukami
  • Radiolabeled neuropeptide y y5 receptor antagonists
    Publication number: 20040192705
    Abstract: The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.
    Type: Application
    Filed: January 22, 2004
    Publication date: September 30, 2004
    Inventors: H. Donald Burns, Raymond E Gibson, Terence G Hamill, Takehiro Fukami
  • Radiolabeled farnesyl-protein transferase inhibitors
    Patent number: 6458935
    Abstract: The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: October 1, 2002
    Assignee: Merck & Co., Inc.
    Inventors: H. Donald Burns, Terence G. Hamill, Raymond E. Gibson
  • F-18 radiolabeled neurokinin-1 receptor antagonists
    Patent number: 6241964
    Abstract: The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: June 5, 2001
    Assignee: Merck & Co., Inc.
    Inventors: H. Donald Burns, Terence G. Hamill, Raymond E. Gibson
  • Gamma emitting, CCK-A antagonists for pancreatic imaging
    Patent number: 4994258
    Abstract: Novel radiolabeled cholecystokinin-A (CCK-A) antagonists have been developed which, after intravenous injection, localize in the pancreas as a result of specific binding to CCK-A receptors. These tracers, when labeled with appropriate radiohalogens, are useful as commercial diagnostic imaging radiopharmaceuticals and radiotherapeutic drugs.
    Type: Grant
    Filed: March 5, 1990
    Date of Patent: February 19, 1991
    Assignee: Merck & Co., Inc.
    Inventors: H. Donald Burns, Nancy J. Brenner, Raymond E. Gibson, Howard F. Solomon